What is CCCC's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.39B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CCCC?

P/E (TTM) is n/a and 52-week range is $1.69 to $5.17 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CCCC figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CCCC?

The company profile lists revenue (TTM) near $30M, net income (TTM) near $-8.58B, EPS (TTM) near $-1.00 when available from the market-data feed. Figures are informational and may lag live markets.

Where is C4 Therapeutics, Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Watertown, Massachusetts, US, 110.6M shares outstanding, ISIN US12529R1077 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

C4 Therapeutics, Inc

$CCCC

Health Care · Biotechnology

IR Run Scenarios

$3.16

+10.88%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2020-10-02. The firm is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The firm is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. The company is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).

Employees

104

Website

c4therapeutics.com/

IPO

2020-10-02

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)